SG11201407595UA - Generation of human ips cells by a synthetic self- replicative rna - Google Patents

Generation of human ips cells by a synthetic self- replicative rna

Info

Publication number
SG11201407595UA
SG11201407595UA SG11201407595UA SG11201407595UA SG11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA
Authority
SG
Singapore
Prior art keywords
nsp1
nsp4
nsp2
vee
international
Prior art date
Application number
SG11201407595UA
Other languages
English (en)
Inventor
Steven F Dowdy
Naohisa Yoshioka
Original Assignee
Univerisity Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerisity Of California filed Critical Univerisity Of California
Publication of SG11201407595UA publication Critical patent/SG11201407595UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
SG11201407595UA 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna SG11201407595UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649876P 2012-05-21 2012-05-21
US201361798229P 2013-03-15 2013-03-15
PCT/US2013/041980 WO2013177133A2 (fr) 2012-05-21 2013-05-21 Génération de cellules ips humaines par un arn de synthèse auto-réplicatif

Publications (1)

Publication Number Publication Date
SG11201407595UA true SG11201407595UA (en) 2014-12-30

Family

ID=49624495

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407595UA SG11201407595UA (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Country Status (14)

Country Link
US (4) US9862930B2 (fr)
EP (1) EP2852671B1 (fr)
JP (1) JP6396893B2 (fr)
CN (1) CN104508131B (fr)
AU (1) AU2013266496B2 (fr)
CA (1) CA2873964A1 (fr)
DK (1) DK2852671T3 (fr)
ES (1) ES2698527T3 (fr)
HU (1) HUE041853T2 (fr)
IL (2) IL235628B (fr)
PL (1) PL2852671T3 (fr)
PT (1) PT2852671T (fr)
SG (1) SG11201407595UA (fr)
WO (1) WO2013177133A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
WO2017087763A1 (fr) * 2015-11-18 2017-05-26 Orbis Health Solutions Llc Système de vecteur viral alpha t7
US20190352604A1 (en) * 2017-02-24 2019-11-21 Koji Tanabe Nerve cell production method
CN110352238A (zh) * 2017-02-24 2019-10-18 田边刚士 诱导性多能干细胞的制作方法
JP2020526515A (ja) 2017-07-05 2020-08-31 ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子
EP3681993A1 (fr) * 2017-09-13 2020-07-22 BioNTech RNA Pharmaceuticals GmbH Réplicon d'arn pour la reprogrammation de cellules somatiques
US11229699B2 (en) * 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
EP3719133A4 (fr) * 2017-11-30 2021-08-11 I Peace, Inc. Méthode de production de cellules neurales
KR102143320B1 (ko) * 2018-08-28 2020-08-12 주식회사 스템랩 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법
EP3864027A1 (fr) * 2018-10-08 2021-08-18 Janssen Pharmaceuticals, Inc. Réplicons à base d'alphavirus pour l'administration d'agents biothérapeutiques
US20200224174A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of constructs derived from viruses
EP3990648A1 (fr) * 2019-06-27 2022-05-04 EMD Millipore Corporation Expansion cellulaire avec des vecteurs d'arn auto-réplicatifs exprimant des protéines d'immortalisation
EP4085130A4 (fr) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus
EP4119166A1 (fr) 2020-03-12 2023-01-18 Institute for Basic Science Composition pour induire l'apoptose de cellules ayant une variation de séquence génomique et procédé pour induire l'apoptose de cellules à l'aide de la composition
US20230220025A1 (en) * 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子系统及其制备和应用
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
TW202300642A (zh) 2021-03-25 2023-01-01 美商藍岩醫療公司 獲得誘導型多能幹細胞之方法
AU2022269877A1 (en) * 2021-05-04 2023-12-21 Mogrify Limited Cell conversion
US20230046606A1 (en) * 2021-07-15 2023-02-16 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
US20230044997A1 (en) * 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
WO2023288285A1 (fr) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Vecteurs d'expression polycistronique
WO2023122517A2 (fr) * 2021-12-20 2023-06-29 Elevatebio Technologies, Inc. Compositions et procédés pour la reprogrammation cellulaire à l'aide d'arn circulaire
WO2023212722A1 (fr) 2022-04-28 2023-11-02 Bluerock Therapeutics Lp Nouveaux sites d'intégration génomique sûre et leurs procédés d'utilisation
WO2023250197A2 (fr) 2022-06-23 2023-12-28 Turn Biotechnologies, Inc. Structures lipidiques et compositions les comprenant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix Inc Verbindungen und ihre Verwendung in einer binären Synthesestrategie
EP0907746B1 (fr) * 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Vecteurs a base d'alphavirus de recombinaison, presentant une inhibition reduite de la synthese macromoleculaire cellulaire
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
EP1386926A1 (fr) 2002-07-29 2004-02-04 Bioxtal Procédés de préparation de polypeptides marqués recombinants et leur utilisation
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
KR101454842B1 (ko) 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US9005966B2 (en) * 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (fr) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Utilisation d'ARN pour la reprogrammation de cellules somatiques
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
WO2009115295A1 (fr) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vecteurs et procédés de génération de cellules souches pluripotentes induites (ips) sans vecteur à l'aide d'une recombinaison dirigée
ES2644588T3 (es) * 2008-06-13 2017-11-29 Whitehead Institute For Biomedical Research Programación y reprogramación de células
WO2010028019A2 (fr) 2008-09-03 2010-03-11 The General Hospital Corporation Reprogrammation directe de cellules somatiques à l'aide de vecteurs non intégrants
JP5553289B2 (ja) * 2009-02-27 2014-07-16 国立大学法人京都大学 新規核初期化物質
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
WO2010120785A2 (fr) 2009-04-13 2010-10-21 The Regents Of The University Of California Procédés et compositions pour cultiver des cellules souches
US20130196865A1 (en) * 2010-03-03 2013-08-01 The General Hospital Corporation Method for selecting an ips cell
WO2011130624A2 (fr) * 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Expression de polypeptide prolongée à partir d'arn synthétiques modifiés et utilisations de celle-ci
JP6353846B2 (ja) * 2012-11-09 2018-07-04 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 細胞のｒｎａ発現方法

Also Published As

Publication number Publication date
JP6396893B2 (ja) 2018-09-26
US10370646B2 (en) 2019-08-06
ES2698527T3 (es) 2019-02-05
PT2852671T (pt) 2018-11-29
EP2852671B1 (fr) 2018-08-22
AU2013266496A1 (en) 2014-11-27
US9862930B2 (en) 2018-01-09
EP2852671A4 (fr) 2015-12-23
HUE041853T2 (hu) 2019-05-28
AU2013266496B2 (en) 2018-08-09
DK2852671T3 (en) 2018-12-10
CN104508131A (zh) 2015-04-08
US20150159143A1 (en) 2015-06-11
IL235628B (en) 2020-03-31
PL2852671T3 (pl) 2019-06-28
EP2852671A2 (fr) 2015-04-01
WO2013177133A2 (fr) 2013-11-28
US20210108179A1 (en) 2021-04-15
WO2013177133A3 (fr) 2014-03-20
IL272917A (en) 2020-04-30
JP2015519898A (ja) 2015-07-16
US20180216079A1 (en) 2018-08-02
US10793833B2 (en) 2020-10-06
CA2873964A1 (fr) 2013-11-28
US20190338252A1 (en) 2019-11-07
IL235628A0 (en) 2015-01-29
CN104508131B (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
SG11201407595UA (en) Generation of human ips cells by a synthetic self- replicative rna
SG11201407427WA (en) Extreme pcr
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201804400SA (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407702XA (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201810782TA (en) Elastomeric copolymers based on [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and their use in the preparation of rubbers
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201903450YA (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
SG11201407867VA (en) Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
SG11201408561YA (en) Tunable materials
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201407635XA (en) Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201805052YA (en) Therapeutic methods using erythrocytes